Nortropyl-1-alkanol derivatives as antiischemic agents

ABSTRACT

2-(8-Azabicyclo[3.2.1]oct-8-yl)alkanols of the formula ##STR1## wherein Q is S or CH=CH; X is H, OH or another aromatic substituent; R is hydrogen, alkyl, alkenyl or alkynyl; Y and Y 1  are taken together and are arylmethylene or aralkylmethylene (or a corresponding epoxy derivative) or Y and Y 1  are taken separately and Y is hydrogen or OH, and Y 1  is aryl, aralkyl, arylthio, or aryloxy; and structurally related 2-(piperidino)alkanols; pharmaceutical compositions thereof; methods of treating CNS disorders therewith; and intermediates useful in the preparation of said compounds.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of copending InternationalApplication No. PCT/US90/00292, filed Jan. 16, 1990, entitled"2-Piperidino-1-Alkanol Derivatives as Antiischemic Agents", which is acontinuation-in-part of copending International Application No.PCT/US89/02176, filed May 17, 1989, entitled "2-Piperidino-1-AlkanolDerivatives as Antiischmemic Agents" (now abandoned).

BACKGROUND OF THE INVENTION

The present invention is directed to neuroprotective (antiischemic andexcitory aminoacid receptor blocking) 2-piperidino-1-alkanol derivativesdefined by the formulas (I), (II) and (III) below; pharmaceuticallyacceptable salts thereof; a method of using these compounds in thetreatment of stroke or CNS degenerative diseases such as Alzheimer'sdisease, Huntington's disease and Parkinson's disease; and to certainintermediates therefor.

Ifenprodil is a racemic, so-called dl-erythro compound having therelative stereochemical formula ##STR2## which is marketed as ahypotensive agent, a utility which is marketed as a hypotens shared by anumber of close analogs; Carron et al., U.S. Pat. No. 3,509,164; Carronet al., Drug Res., v. 21, pp. 1992-1999 (1971). More recently,ifenprodil has been shown to possess antiischemic and excitory aminoacidreceptor blocking activity; Gotti et al., J. Pharm Exp. Therap., v. 247,pp. 1211-21 (1988); Carter et al., loc. cit., pp. 1222-32 (1988). Seealso French Patent 2546166. A goal, substantially met by the presentinvention, has been to find compounds possessing such neuroprotectiveeffect in good measure, while at the same time having lowered or nosignificant hypotensive effect.

Certain structurally related1-phenyl-3-(4-aryl-4-acyloxypiperidino)-1-propanols have also beenreported to be useful as analgesics, U.S. Pat. No. 3,294,804; and1-[4-(amino- andhydroxy-alkyl)phenyl]-2-(4-hydroxy-4-tolylpiperazino)-1-alkanols andalkanones have been reported to possess analgesic, antihypertensive,psychotropic or antiinflammatory activity, Japanese Kokai 53-02,474 (CA89:43498y; Derwent Abs. 14858A) and 53-59,675 (CA 89:146938w; DerwentAbs. 48671A).

SUMMARY OF THE INVENTION

The present invention is directed to compounds of the formula ##STR3##wherein R is H, (C₁ -C₆)alkyl, (C₂ -C₆)alkenyl or (C₂ -C₆)alkynyl;

X is hydrogen, (C₁ -C₃)alkyl, halo, OR¹, OCOR¹, CO₂ R¹, SR¹, NHR¹,NHCOR¹, CONH₂ or CN;

R¹ is hydrogen or (C₁ -C₃)alkyl;

Q is S or CH═CH;

Y and Y¹ are taken together and are ##STR4## Y and Y¹ are takenseparately, and Y is hydrogen or OH, and Y¹ is ##STR5## Y is hydrogenand Y¹ is ##STR6## n is 0, 1, 2 or 3; m is 0, 1, 2, 3 or 4;

Q¹ is independently a value of Q as defined above;

X¹ is independently a value of X as defined above; and

Z is O, S, SO or SO₂ ;

compounds of the formula ##STR7## wherein D is ##STR8## Y² and Y³ aretaken together and are ##STR9## Y² and Y³ are taken separately, and Y²is OH and Y³ is ##STR10## Y⁹ is ##STR11## and R, R¹, X, X¹, Q, Q¹, n andm are as defined above; and compounds of the formula ##STR12## whereinY⁴ is H; and

R, R¹, Q, Q¹, X, X¹ and Z are as defined above; and the pharmaceuticallyacceptable acid addition salts of these compounds.

The expression "pharmaceutically acceptable acid addition salts" isintended to include but is not limited to such salts as thehydrochloride, hydrobromide, hydroiodide, nitrate, hydrogen sulfate,dihydrogen phosphate, mesylate, maleate, and succinate. Such salts areconventionally prepared by reacting the free base form of the compound(I), (II) or (III) with an appropriate acid, usually one molarequivalent, and in a solvent. Those salts which do not precipitatedirectly are generally isolated by concentration of the solvent and/oraddition of a non-solvent.

The preferred compounds of the present invention generally have R asmethyl and possess 1S*,2S* or threo relative stereochemistry at the 1-and 2-positions of the propanol chain, i.e., ##STR13##

Furthermore, regardless of the value of R, preferred compounds of thepresent invention are of the formula (I) or (II) having Y and Y¹ or Y²and Y³ taken separately, further having Y or Y² as OH, or Y¹ as --Z(C₄H₃ Q¹ ; or are of the formula (III). The preferred value of Z in allcases is S.

The present invention is also directed to pharmaceutical compositionsand to methods of treating a mammal, particularly man, suffering acentral nervous disorder, which comprises administering to said mammal aneuroprotective effective amount of a compound of the formula (I), (II)or (III). Said compositions and methods are particularly valuable in thetreatment of stroke, Alzheimer's disease, Parkinson's disease,Huntington's disease and related disorders of the central nervoussystem.

The present invention is further directed to intermediate compounds ofthe formula ##STR14## wherein A and B are taken together and are oxygen,forming, together with the carbon to which they are attached a carbonylgroup, or A and B are taken separately and A is hydrogen and B ishydroxy;

X² is hydrogen, (C₁ -C₃)alkyl, halo, OR¹, OR², COOR¹, OCOR¹, SR¹, SR²,NHR¹, NR¹ R³, NHCOR¹, CONH₂ or CN;

R¹ is hydrogen or (C₁ -C₃)alkyl;

R² is a conventional hydroxy or mercaptan protecting group;

R³ is a conventional amino protecting group;

Y⁵ and Y⁶ are taken together and are ##STR15## Y⁵ and Y⁶ are takenseparately and Y⁵ is hydrogen or OH, and Y⁶ is ##STR16## Y⁵ is hydrogenand Y⁶ is ##STR17## X³ is independently a value of X² as defined above;with the proviso that when A and B are taken separately, at least one ofX² and X³ is Or², SR² or NR¹ R³ ;

Z is O, S, SO and SO₂ ; and

R, Q, Q¹, n and m are as defined above;

intermediate compounds of the formula ##STR18## wherein E is ##STR19##Y⁷ and Y⁸ are taken together and are ##STR20## Y⁷ and Y⁸ are takenseparately, and Y⁷ is OH and Y⁸ is ##STR21## Y¹⁰ is ##STR22## and A, B,R, R¹, R², R³, Q, Q¹, X², X³, n and m are as defined above, with thesame proviso concerning A and B;

and intermediate compounds of the formula ##STR23## wherein all groupsare defined as above, with the same proviso concerning A and B.

Those compounds of the formula (I) or (IV) specified as endo have thehydroxy group or oxirane oxygen on the same side of the piperidine ringas the ethylene bridge.

It will be noted that those compounds of the formula (I) to (VI) whichare 1-alkanols possess an asymmetric C-1 carbon, while those wherein Ris other than hydrogen possess a second asymmetric center at the C-2carbon of the alkanol. Similarly, in those compounds of the formulas(IV) to (VI) which are 1-alkanones wherein R is other than hydrogenpossess a C-2 asymmetric carbon. It will be evident to those skilled inthe art of organic chemistry, therefore, that such compounds can beresolved into optical isomers showing equal but opposite rotation ofplane polarized light. For example, all of these compounds arepotentially resolved by fractional crystallization of theirdiastereomeric addition salts with an optically active acid, asexemplified below; while the alcohols are also potentially resolved bychromatography or fractional crystallization of esters derived byreaction with activated forms of optically active acids or withoptically active isocyanates. Alternatively, optically active forms ofcertain of the present compounds are obtained by reaction of anappropriate amine with an optically active epoxide, as also exemplifiedbelow. Thus, the present invention should not be construed as limited tothe racemic forms of the present compounds.

DETAILED DESCRIPTION OF THE INVENTION

The compounds of the present invention, having the formula (I), (II) and(III) defined above, are readily and generally prepared by nucleophilicdisplacement followed by reduction of the resulting ketone to alcohol asdetailed below.

The precursor ketones are generally initially prepared with --OH, --SHand --NHR¹ groups in protected form i.e., as --OR², --SR² or --NR¹ R³groups in the compounds of the formulas (IV), (V) and (VI) where A and Bare taken together as oxygen to form a carbonyl group. Such protectedketones are generally formed by nucleophilic displacement of anappropriately substituted 2-halo, 2-alkanesulfonyloxy- or2-arylsulfonyloxy-1-alkanone with an appropriately substitutedpiperidine derivative, e.g., ##STR24## wherein X⁴ is typically chloro,bromo, mesyloxy or tosyloxy. This reaction is carried out underconditions typical of nucleophilic displacements in general. Where thetwo reactants are about equivalent in availability, close tosubstantially molar equivalents may be used; although when one is morereadily available, it is usually preferred to use that one in excess, inorder to force this bimolecular reaction to completion in a shorterperiod of time. The reaction is generally carried out in the presence ofat least 1 molar equivalent of a base, the piperidine derivative itself,if it is readily available, but more usually a tertiary amine which isat least comparable in base strength to the nucleophilic piperidine; andin a reaction inert solvent such as ethanol. If desired, the reaction iscatalyzed by the addition of up to one molar equivalent or more of aniodide salt (e.g., NaI, KI). Temperature is not critical, but willgenerally be somewhat elevated in order to force the reaction tocompletion within a shorter time period, but not so high as to lead toundue decomposition. A temperature in the range of 50-120° C. isgenerally satisfactory. Conveniently, the temperature is the refluxtemperature of the reaction mixture.

As used in the preceding paragraph, and elsewhere herein, the expression"reaction inert solvent" refers to any solvent which does not interactwith starting materials, reagents, intermediates or products in a mannerwhich adversely affects the yield of the desired product.

If desired, those ketone intermediates having OH, SH or NHR¹ groups inprotected form (OR², SR² or NR¹ R³) can be deprotected at this stage byconventional methods. For example, when R² is triisopropylsilyl ortert-butyldimethylsilyl, the protecting group is conveniently removed byreaction with tetrabutylammonium fluoride (generally, substantially 2molar equivalents) in a reaction inert solvent such as tetrahydrofuran.When R² is benzyl or R³ is benzyloxycarbonyl, the protecting group willgenerally be removed by conventional hydrogenolysis over a noble metalcatalyst in a reaction inert solvent, e.g., using 10% Pd/C as catalyst,preferably at low pressures (e.g., 1-10 atmospheres) and temperatures(e.g., 20-75° C.) and generally in a reaction inert solvent such asmethanol.

Generally excluding ketone intermediates containing ester groups orprotecting groups such as benzyloxycarbonyl (which will generally beremoved prior to ketone reduction), but otherwise with or without priorremoval of protecting groups, the ketone intermediates are convenientlyconverted to corresponding alcohols by conventional reduction with aLiAlH₄, usually in excess (e.g., mol for mol), in a reaction inertsolvent such as tetrahydrofuran at reduced temperature (e.g., -15° C. to15° C.). Alternatively, ketone intermediates, particularly thosecontaining ester groups, are reduced with a milder hydride reducingagent such as NaBH4, again usually in excess, now in a protic solventsuch as methanol or ethanol, generally at somewhat higher temperature,e.g., 15-45° C.

Any protecting groups which are still in place after ketone reductionare then removed according to the methods described above. Certain othertransformations, such as olefin hydrogenation, epoxidation andsodium/liquid NH reduction of epoxides, e.g., ##STR25## are alsooptionally carried out late in the synthetic sequence, e.g., aftercoupling to form ketone, after removal of protecting groups (so long asthe unprotected groups do not interfere with the transformations) and/orafter reduction of ketone to alcohol.

Said epoxidations are readily accomplished, for example, by reacting amethylene compound with substantially one molar equivalent ofm-chloroperbenzoic acid in a reaction inert solvent such as CH₂ Cl₂. Thereduction of epoxide to alcohol is readily accomplished by conventionalsodium/liquid ammonia, generally carried out at temperatures below theboiling point of liquid NH₃ (e.g., at -78° C., the temperature of anacetone-dry ice bath) in the presence of a reaction inert solvent suchas tetrahydrofuran.

The starting materials and reagents required for the synthesis of thecompounds of the present invention are readily available, eithercommercially, according to literature methods, or by methods exemplifiedin Preparations below.

The present compounds of the formula (I), (II) and (III) possessselective neuroprotective activity, based upon their antiischemicactivity and ability to block excitory aminoacid receptors, while at thesame time generally having lowered or no significant hypotensiveactivity. The antiischemic activity of the present compounds isdetermined according to one or more of the methods which have beendetailed previously by Gotti et al. and Carter et al. cited above, or bysimilar methods. The ability of the compounds of the present inventionto block excitatory amino acid receptors is demonstrated by theirability to block N-methyl-D-aspartic acid-induced (NMDA) elevations ofcGMP in neonatal rat cerebellums according to the following procedure.Cerebellums from ten 8-14 day old Wistar rats are quickly excised andplaced in 4° C. Krebs/bicarbonate buffer, pH 7.4 and then chopped in 0.5mm×0.5 mm sections using a McIlvain tissue chopper (The NickleLaboratory Engineering Co., Gomshall, Surrey, England). The resultingpieces of cerebellum are transferred to 100 ml of Krebs/bicarbonatebuffer at 37° C. which is continuously equilibrated with 95:5 O₂/CO.sub. 2. The pieces of cerebellum are incubated in such a manner forninety minutes with three changes of the buffer. The buffer then isdecanted, the tissue centrifuged (1 min., 3200 r.p.m.) and the tissueresuspended in 20 ml of the Krebs/bicarbonate buffer. Then, 250 μlaliquots (approximately 2 mg) are removed and placed in 1.5 ml microfugetubes. To those tubes are added 10 μl of the compound under study from astock solution followed, after a 10 minute incubation period, by 10 μlof a 2.5 mM solution of NMDA to start the reaction. The final NMDAconcentration is 100 μM. Controls do not have NMDA added. The tubes areincubated for one minute at 37° C. in a shaking water bath and then 750μl of a 50 mM Tris-Cl, 5 mM EDTA solution is added to stop the reaction.The tubes are placed immediately in a boiling water bath for fiveminutes. The contents of each tube then are sonicated for 15 secondsusing a probe sonicator set at power level three. Ten microliters areremoved and the protein determined by the method of Lowry, Anal.Biochem. 100:201-220 (1979). The tubes are then centrifuged (5 min.,10,000 xg), 100 μl of the supernatant is removed and the level of cyclicGMP (cGMP) is assayed using a New England Nuclear (Boston, Mass.) cGMPRIA assay according to the method of the supplier. The data is reportedas pmole cGMP generated per mg. protein. Undesired hypotensive activityis also determined by known methods, for example, according to themethods of Carron et al., also cited above.

Such selective neuroprotective antiischemic and excitatory amino acidblocking activities reflect the valuable utility of the presentcompounds in the treatment of degenerative CNS (central nervous system)disorders such as stroke; and Alzheimer's disease, Parkinson's diseaseand Huntington's disease; without significant potential for concurrentundue drop in blood pressure. In the systemic treatment of such diseaseswith a neuroprotective amount of compounds of the formula (I), (II) or(III), the dosage is typically from about 0.02 to 10 mg/kg/day (1-500mg/day in a typical human weighing 50 kg) in single or divided doses,regardless of the route of administration. Of course, depending upon theexact compound and the exact nature of the individual illness, dosesoutside this range may be prescribed by the attending physician. Theoral route of administration is generally preferred. However, if thepatient is unable to swallow, or oral absorption is otherwise impaired,the preferred route of administration will be parenteral (i.m., i.v.) ortopical.

The compounds of the present invention are generally administered in theform of pharmaceutical compositions comprising at least one of thecompounds of the formula (I), (II) or (III), together with apharmaceutically acceptable vehicle or diluent. Such compositions aregenerally formulated in a conventional manner utilizing solid or liquidvehicles or diluents as appropriate to the mode of desiredadministration: for oral administration, in the form of tablets, hard orsoft gelatin capsules, suspensions, granules, powders and the like; forparenteral administration, in the form of injectable solutions orsuspensions, and the like; and for topical administration, in the formof solutions, lotions, ointments, salves and the like.

The present invention is illustrated by the following examples, but isnot limited to the details thereof.

All non-aqueous reactions were run under nitrogen for convenience andgenerally to maximize yields. All solvants/diluents were dried accordingto standard published procedures or purchased in a predried form. Allreactions were stirred either magnetically or mechanically. NMR spectraare recorded at 300 MHz and are reported in ppm. The NMR solvent wasCDCl₃ unless otherwise specified. IR spectra are reported in cm⁻¹,generally specifying only strong signals.

EXAMPLE 12-(3-Phenylmethylene-8-azabicyclo[3.2.1]oct-8-yl)-1-(4-(triisopropylsilyloxy)phenyl)-1-propanone

A mixture of 3-phenylmethylene-8-azabicyclo[3.2.1]octane (1.09 g, 4.87mmol), 4-(triisopropylsiloxy)-alpha-bromopropiophenone (1.88 g, 4.88mmol) and triethylamine (1.5 ml, 10.76 mmol) in ethanol (75 ml) wasrefluxed 22 hours. After cooling, ether (50 ml) was added and themixture was filtered through diatomaceous earth. The filtrate wasconcentrated and chromatographed on silica gel (2×6 inches, hexane thenethyl acetate/hexane gradient) to give 0.56 g (23%) of an orange oilproduct; NMR 8.18 (d, 2H), 7.25 (t, 2H), 7.12 (d, 3H), 6.86 (d, 2H),6.29 (s, 1H), 4.08 (m, 1H), 3.47-3.26 (m, 2H), 2.75 (m, 1H), 2.57-2.37(m, 2H), 2.03-1.72 (m, 4H), 1.6 (m, 1H; partially under water peak fromNMR solvent), 1.40 (d, 3H), 1.25 (m, 3H), 1.09 (d, 18H).

EXAMPLE 2 Mixture of (1R*,2S*)- and(1S*,2S*)-2-(3-phenylmethylene-8-azabicyclo[3.2.1]oct-8-yl)-1-(4-(triisopropylsilyloxy)phenyl)-1-propanol

To a slurry of LiAlH₄ (0.61 g, 16.07 mmol) in tetrahydrofuran (50 ml) at0° C. was added title product of the preceding Example (8.04 g, 15.96mmol) in tetrahydrofuran (150 ml) over 15 minutes. The mixture wasstirred 15.5 hours at room temperature, then carefully quenched withwater (1.2 ml), filtered over diatomaceous earth and concentrated togive a yellow oil (7.15 g, 89%). This mixture of racemic title productswas used directly in the next reaction without purification.

EXAMPLE 3 (1S*,2S*)- and(1R*,2S*)-1-(4-hydroxyphenyl)-2-(3-phenylmethylene-8-azabicyclo[3.2.1]oct-8-yl)-1-propanol

Title product of the preceding Example (7.15 g, 14.14 mmol) wasdissolved in tetrahydrofuran (250 ml) and tetrabutylammonium fluoride(28.5 ml, 28.5 mmol, 1M in tetrahydrofuran) was added all at once. Thesolution was stirred at room temperature 18 hours, then concentrated andchromatographed on silica gel (4×6 inches, ethyl acetate/hexane gradientfollowed by methanol/ethyl acetate gradient) to give first the racemic(1S*,2S*)-title product (1.58 g) followed by the more polar racemic(1R*,2S*)-title product (2.88 g). (Note that because of the asymmetry inthe 3-phenylmethylene-8-azabicyclo[3.2.1]oct-8-yl side chain, each ofthese products is actually a mixture of two racemates). The(1S*,2S*)-product was recrystallized from ethyl acetate/hexane to give0.923 g of white solid; mp 175-177° C.; NMR includes 4.10 (t, J=7.7Hz,1H); Anal. C 78.77, H 7.90, N 3.92, calcd. C 79.05, H 7.90, N 3.92.

The (1R*,2S*)-product was further purified by radial chromatography with60% ethyl acetate/hexane elution to give 0.24 g of colorless oil. Thisoil was crystallized from ether/hexane to give 0.17 g of fluffy solid,mp 78.5-85° C. The latter was converted to its HCl salt by bubbling HClgas into an ether solution of the compound for 3 minutes. The whiteprecipitate was collected and recrystallized from ethanol to yield the(1R*,2S*)-hydrochloride salt as its half hydrate; mp 215-218° C.; NMR(DMSO-d₆) includes 5.17 (s, 1H) and 4.60-3.93 (m, 2H); Anal. C 70.00, H7.45, N 3.35, calcd. for 1/2 H₂ O C 69.95, H 7.40, N 3.54.

EXAMPLE 42-(4-(Phenylthio)piperidino)-1-(4-(tert-butyldimethylsilyloxy)phenyl)-1-propanone

This product was prepared according to the procedure of Example 1 using4-phenylthiopiperidine (1.13 g, 5.85 mmol), triethylamine (0.82 ml, 5.88mmol), and 4-(tert-butyldimethylsilyloxy)-alpha-bromopropiophenone (2.0g, 5.83 mmol) and a reflux time of 21.5 hours. The product was isolatedby silica gel flash chromatography with an ethyl acetate/hexane gradientelution. The yield was 1.29 g of title product as a yellow oil: NMR 8.00(d, J=9Hz, 2H), 7.35 (d, J=7.8Hz, 2H), 7.25 (m, 3H), 6.81 (d, J=8.4Hz,2H), 4.00 (q, J=6.8Hz, 1H), 3.03 (m, 1H), 2.91-2.87 (m, 1H), 2.80-2.76(m, 1H), 2.44 (dt, J=9.5, 2.6Hz, 1H), 2.29-2.19 (m, 1H), 1.93-1.85 (m,2H), 1.66-1.52 (m, 2 H--partially under water peak from solvent), 1.22(d, J=7.1 Hz, 3H), 0.97 (s, 9H), 0.22 (s, 6H). Later fractions from thechromatography yielded an additional 0.51 g of product which haddesilylated during the reaction. This material could also be convertedto the final targeted compounds by procedures below.

By the same methods 4-(triisopropylsilyloxy)alpha-bromopropiophenone(9.97 g, 25.9 mmol) was converted to chromatographed2-(4-(phenylthio)piperidino)-1-(4-(triisopropylsilyloxy)phenyl)-1-propanoneas a light orange oil: 8.32 g; NMR 8.00 (d, J=8.8Hz, 2H), 7.37 (dd,J=1.5, 8.4Hz, 2H), 7.29-7.18 (m, 3H), 6.86 (d, J=8.8Hz, 2H), 4.02 (q,J=6.8Hz, 1H), 3.08-3.00 (m, 1H), 2.85 (d, J=26.2Hz, 1H), 2.75 (d, J=16.6Hz, 1H), 2.45 (dt, J=11, 2.6Hz, 1H), 2.23 (dt, J=9.8, 2.5Hz, 1H),1.96-1.88 (m, 2H), 1.71-1.50 (m, 5H), 1.09 (d, J=7Hz, 18H).

EXAMPLE 5 (1S*,2S*)- and (1R*,2S*)-2-(4-Phenylthio)piperdino)-1(4-(triisopropylsilyloxy)phenyl)-1-propanol

By the method of Example 2, the triisopropylsilyloxy product of thepreceding Example (8.32 g, 16.7 mmol), using chromatography on silicagel with ethyl acetate/hexane gradient elution to separate the isomers,was converted to 6.06 g of less polar (1S*, 2S*)-title product as anoil; NMR 7.41 (d, J=6.7Hz, 2H), 7.32-7.24 (m, 3H), 7.15 (d, J=8.5Hz,2H), 6.82 (d, J=8.4Hz, 2H), 4.14 (d, J=9.7Hz, 1H), 3.11 (m, 1H), 2.88(m, 1H), 2.69 (m, 1H), 2.69-2.55 (m, 2H), 2.21 (t, 1H), 2.03 (m, 2H),1.85-1.58 (m, 3H), 1.35-1.20 (m, 2H), 1.23 (d, J=15Hz, 18H), 1.07 (d, J=7Hz, 3H); and to 0.2 g of more polar (1R*,2S*)-title product; NMR 7.35(d, J=7Hz, 2H), 7.28-7.16 (m, 3H), 7.08 (d, J=9Hz, 2H), 6.78 (d, J=9Hz,2H), 4.68 (d, J=5Hz, 1H), 3.10-2.98 (m, 1H), 2.98-2.87 (m, 1H),2.75-2.60 (m, m, 2H), 2.33 (t, J=9Hz, 1H), 2.16 (t, J=11 Hz, 1H), 1.91(t, J=15Hz, 2H), 1.70-1.48 (m, 2H), 1.32-1.12 (m, 4H), 1.06 (d, J=9Hz,18H), 0.88-0.78 (m, 3H).

EXAMPLE 6(1S*,2S*)-1-(4-Hydroxyphenyl)-2-(4-(phenylthio)piperidino)-1-propanolMethod A

To a slurry of LiAlH₄ (0.11 g, 2.9 mmol) in tetrahydrofuran (25 ml)chilled to 0° C. was added title product of Example 4 (1.29 g, 2.83mmol) in tetrahydrofuran (50 ml). The reaction was warmed to ambienttemperature for 2 hours, refluxed for 3 hours, and left to stir for 72hours. The mixture was carefully quenched with water and filteredthrough diatomaceous earth. The filtrate was concentrated to a wetsolid, which was taken up in ethyl acetate and washed with brine, dried(CaSO₄), concentrated to afford 0.41 g of white solid, andrecrystallized from ether/hexane to give 0.16 g of title product; mp155-157° C.; NMR includes 4.12 (d, 1H); Anal. C 69.57, H 7.28, N 3.95,calcd. C 69.94, H 7.34, N 4.08. The alumina salts from the reaction wereSohxlet extracted with ethyl acetate for 24 hours. Concentration gave anadditional 0.3 g of product.

Method B

The same product is obtained from the (1S*, 2S*)-title product of thepreceding Example by the method of Example 3.

EXAMPLE 7(1R*,2S*)-1-(4-Hydroxyphenyl)-2-(4-(phenylthio)piperidino)-1-propanol

Following the procedure of Example 3, present title product was obtainedfrom the (1R*,2S*)-title of Example 5 (0.2 g, 0.4 mmol) andtetrabutylammonium fluoride (0.8 ml, 0.8 mmol: 1M in tetrahydrofuran) intetrahydrofuran (5 ml) at ambient temperature for 72 hours. The productwas obtained by silica gel flash chromatography (6×1 inches, ethylacetate/hexane gradient elution) to give 0.14 g of semi-solid.Recrystallization from methylene chloride/hexane gave 0.056 g of whitesolid; mp 124.5-126° C; NMR includes 4.72 (d, J=4.1 Hz, 1H); Anal. C69.68, H 7.24, N 4.14, calcd. C 69.94, H 7.34, N 4.08.

EXAMPLE 8(1S*,2S*)-1-(4-Hydroxyphenyl)-2-(4-(phenylsulfonyl)piperidino)-1-propanol

Title product of Example 6 (0.13 g, 0.378 mmol) was dissolved in CH₂ Cl₂(20 ml) and m-chloroperoxybenzoic acid (0.23 g, 1.133 mmol) was addedall at once. The solution was stirred 23 hours, then the precipitatedmaterial was filtered to give 0.154 g of white solid which was the crudeintermediate N-oxide. The latter was hydrogenated in a Parr apparatus inmethanol (20 ml) with 10% palladium on carbon catalyst (0.03 g) at 50psig hydrogen. The reaction was complete in 6 hours and was filteredthrough diatomaceous and concentrated to leave 0.166 g of yellow oil.This oil was taken up in CH₂ Cl₂ and washed with saturated sodiumbicarbonate. The organic phase was dried (MgSO₄) and concentrated togive 0.106 g of yellow oil, which was crystallized from ethylacetate/hexane to yield 0.076 g of white solid; mp 169-175° C. A portionof the product (0.045-0.050 g) was further purified by mixing vigorouslywith saturated sodium bicarbonate and ethyl acetate for 15 minutes. Thephases were separated and the aqueous was further extracted with ethylacetate (2x). The combined organic phase was dried (CaSO₄), concentratedto give a colorless oil, and crystallized from ethyl acetate to give0.02 g of white powder; mp 195-196° C.; NMR 7.88 includes 4.15 (d,J=9.7Hz, 1H); Anal. C 63.77, H 6.61, N 3.61, calcd. C 63.98, H 6.71, N3.73.

EXAMPLE 9(1S*,2S*)-1-(4-Hydroxyphenyl)-2-(4-(phenylsulfinyl)piperidino)-1-propanol

Title product of Example 6 (0.5 g, 1.46 mmol) was dissolved in CH₂ Cl₂(40 ml) and m-chloroperoxybenzoic acid (0.3 g, 1.48 mmol) was added allat once. After stirring overnight at ambient temperature, the mixturewas concentrated directly onto silica gel and flash chromatographed (6×1inches, ethyl acetate/hexane gradient) to give 0.34 g of crude productas a white solid which was further purified by partitioning betweensaturated NaHCO₃ and ethyl acetate with vigorous stirring for 20minutes. The phases were separated and the organic layer wasconcentrated to leave a greasy solid which was crystallized from ethylacetate/hexane to give 0.122 g of white solid; mp 110° C.; NMR includes4.16 (long range coupled d, J=9.7 Hz, 1H); HRMS 360.1635, calcd.360.1626.

EXAMPLE 101-(4-(Benzyloxy)phenyl)-2-(4-benzyl-4-hydroxypiperidino)-1-propanone

This product was prepared following the procedure of Example 1 from4-hydroxy-4-benzylpiperidine (2.0 g, 10.46 mmol), triethylamine (1.46ml, 10.47 mmol), and 4-benzyloxy-alpha-bromopropiophenone (3.33 g, 10.43mmol) in ethanol (50 ml) with a reflux period of 24 hours. The presentracemic product was obtained after silica gel flash chromatography withethyl acetate/hexane gradient elution. The yield was 2.88 g (64%) of ayellow solid; NMR 8.06 (d, 2H), 7.52-7.08 (m, 10H), 6.97 (d, 2H), 5.11(s, 2H), 4.00 (q, 1H), 2.72 (s, 2H), 2.72-2.53 (m, 2H), 2.43 (t, 1H),1.85-1.39 (m, 6H), 1.23 (d, 3H). HRMS 412.2348, calcd. (--OH) 412.2273.

EXAMPLE 11(1S*,2S*)-1-(4-(Benzyloxy)phenyl)-2-(4-benzyl-4-hydroxypiperidino)-1-propanol

NaBH₄ (0.25 g, 6.61 mmol) was added all at once to a solution of titleproduct of the preceding Example (2.88 g, 6.70 mmol) in ethanol (50 ml).The mixture was stirred 20 hours at ambient temperature as a precipitateformed. The solid was filtered and dried to yield 0.60 g of presenttitle product; mp 147-148° C.; NMR includes 4.17 (d, J=10Hz, 1H); IR(KBr) 3387, 3024, 2936, 2909, 1611, 1513, 1453, 1239, 1026, 1011, 695.The filtrate from the above reaction was concentrated, the residuepartitioned between ethyl acetate and water and the phases separated.The aqueous phase was extracted with ethyl acetate. The combined organicphases were washed with water, dried (CaSO₄) and concentrated to give2.82 g of additional title product.

EXAMPLE 12(1S*,2S*)-1-(4-Hydroxyphenyl)-2-(4-benzyl-4-hydroxypiperidino)-1-propanol

Title product of the preceding Example (0.49 g, 1.14 mmol) andtetrahydrofuran (30 ml) was chilled to -78° C. and ammonia gas (30 ml)was condensed into the mixture. Sodium (0.082 g, 3.57 mmol) was added infour pieces. The reaction, which gradually turned blue, was stirred 15minutes and then quenched with ammonium chloride (0.29 g). The reactionwas allowed to warm to ambient temperature, with the ammonia boilingoff. The reaction was concentrated and the residue was taken up in ethylacetate and washed with water and brine. The organic phase was dried(CaSO₄) and concentrated to give 0.39 g of white solid.Recrystallization from hexane gave 0.19 g of present title product; NMR(DMSO-d₆) 7.25-7.11 (m, 5H), 7.08 (d, J=8.2Hz, 2H), 6.68 (d, J=8.6Hz,2H), 4.14 (s, 1H), 4.09 (d, J=9.2Hz, 1H), 3.33 (s, 2H), 3.30 (s, 1H),2.74 (m, 1H--partially under water peak from the NMR solvent), 2.60-2.35(m, 4H--partially under NMR solvent peak), 1.70-1.44 (m, 4H), 0.63 (d,J=6.7Hz, 3H). Deuterium oxide washed out the singlets at 4.14 and 3.30ppm.

This product was recrystallized from ethyl acetate to give purifiedtitle product; mp 213-214° C.; IR (KBr) 3263, 3023, 2940, 2917, 1615,1517, 1453, 1273, 1221, 1186, 1020, 1011, 831, 687. Anal. C 73.73, H8.03, N 4.01, calcd. C 73.87, H 7.97, N 4.10.

EXAMPLE 13 1-(4-(tert-Butyldimethylsilyloxy)phenyl)-2-(3-phenylthio-8-azabicyclo[3.2.1]oct-8-yl)-1-propanone

Following the procedure of Example 1, this product was prepared from4-tert-butyldimethylsilyloxy-alphabromopropiophenone (1.25 g, 3.65mmol), 3-phenylthio-8-azabicyclo[3.2.1.]octane (0.8 g, 3.65 mmol), andtriethylamine (0.51 ml, 3.65 mmol) in ethanol (30 ml) with an overnightreflux. The product was flash chromatographed on silica gel (10% ethylacetate/hexane elution); 0.889 g (51%); NMR 8.13 (d, J=9Hz, 2H), 7.38(m, 2H), 7.30-7.15 (m, 3H), 6.83 (d, J=9Hz, 2H), 3.93 (q, J=7Hz, 1H),3.42-3.28 (m, 3H), 2.05-1.56 (m, 9H), 1.32 (d, J=7Hz, 3H), 0.99 (s, 9H),0.25 (s, 6H); IR 2940, 2840, 1600, 1390-1290 (br), 910.

EXAMPLE 14 Mixture of (1R*,2S*)- and(1S*,2S*)-1-(4-(tert-Butyldimethylsilyloxy)phenyl)-2-(3-phenylthio-8-azabicyclo[3.2.1]oct-8-yl)-1-propanol

This product was prepared as in Example 2 with overnight stirring atambient temperature from the product of the preceding Example (0.85 g,1.77 mmol) and LiAlH₄ (0.153 g, 4.0 mmol) in tetrahydrofuran (24 ml).The product was isolated as a yellow oil (0.78 g, 91%) as a mixture ofracemic title products.

EXAMPLE 15 (1S*,2S*)- and(1R*,2S*)-1-(4-Hydroxyphenyl)-2-(3-phenylthio-8-azabicyclo[3.2.1]oct-8-yl-1-propanol

Title product of the preceding Example (0.78 g, 1.6 mmol) wasdesilylated according to the procedure of Example 3 withtetrabutylammonium fluoride (1.6 ml, 1.6 mmol; 1M in tetrahydrofuran) ina 5 minute reaction. The resulting mixture of racemates were separatedby silica gel flash chromatography (50% ethyl acetate/hexane elution).(1S*,2S*)-Title product eluted first; 0.133 g; NMR (DMSO d₆) 7.40-7.21(m, 5H), 7.06 (d, J=8.5Hz, 2H), 6.63 (d, J=8.0 Hz, 2H), 4.35 (d,J=5.0Hz, 1H), 3.54-3.40 (m, 2H), 3.35-3.29 (m, 2H), 2.70-2.62 (br t,1H), 2.50 (m, 1H), 1.80-1.54 (m, 6H), 0.63 (d, J=6.5Hz, 3H).

Continued elution gave (1R*,2S*)-title product: 0.102 g; NMR 7.45-7.40(m, 2H), 7.32-7.22 (m, 3H), 7.15 (d, 2H), 6.76 (d, 2H), 4.80 (d, 1H),3.60-3.52 (m, 2H), 3.51-3.38 (m, 1H), 2.80-2.72 (m, 1H), 2.00-1.55 (m,8H), 0.68 (d, 3H). This product (80 mg) was converted to its HCl salt bydissolving in 15ml of ether, bubbling in dry HCl for 2 minutes andtriturating the resulting oily solid with ether to yield 30 mg as awhite solid.

EXAMPLE 162-(4-Benzyl-4-hydroxypiperidino)-1-(4-(triisopropylsilyloxy)phenyl)-1-propanone

This product was prepared according to the procedures of Example 1 from4-hydroxy-4-benzylpiperidine (2.72 g, 14.22 mmol),4-triisopropylsilyloxyalpha-bromopropiophenone (5.48 g, 14.22 mmol), andtriethylamine (2.0 ml, 14.35 mmol) in ethanol (50 ml) with a reflux timeof 17 hours to give 4.92 g (70%) of present, chromatographed titleproduct as an orange oil; NMR 8.01 (d, J=8.8Hz, 2H), 7.31-7.22 (m, 3H),7.18-7.15 (m, 2H), 6.87 (d, J=8.8Hz, 2H), 4.03 (q, J=6.7 Hz, 1H), 2.72(s, 2H), 2.68-2.57 (m, 3H), 2.45 (dt, 1H), 1.78-1.42 (m, 4H), 1.40-1.25(m, 7H), 1.10 (d, J=7 Hz, 18H).

EXAMPLE 17 (1S*,2S*)- and (1R*,2S*)-2-(4-Benzyl-4-hydroxypiperidino)-1-(4-(triisopropylsilyloxy)phenyl)-1-propanol

Title product of the preceding Example (4.92 g, 9.33 mmol) was dissolvedin ethanol (100 ml) and NaBH₄ (0.38 g, 10 mmol) was added all at once.After stirring overnight at ambient temperature, present (1S*,2S*)-titleproduct was recovered by filtration, 2.11 g; NMR 7.46-7.17 (m, 7H), 6.84(d, J=7Hz, 2H), 4.18 (d, J=11 Hz, 1H), 2.86 (br t, 1H), 2.77 (s, 2H),2.70-2.42 (m, 4H), 1.89-1.55 (m, 6H), 1.30-1.13 (m., 3H), 1.10 (d, J=8.6Hz, 18H), 0.75 (d, J=6Hz, 3H).

The filtrate was concentrated and the residue dissolved in ethylacetate, extracted with water (2x) and brine, dried (CaSO₄),concentrated to 2.33 g of a light yellow solid, and flashchromatographed on silica gel (2×6 inches, ethyl acetate/hexane gradientelution) to give first 1.4 g more of (1S*,2S*)-product, followed by 0.46g of (1R*,2S*)-product; NMR 7.33-7.11 (m, 7H), 6.82 (d, J=8.6Hz, 2H),4.77 (d, J=4Hz, 1H), 2.80-2.39 (m, 5H), 1.88-1.43 (m, 6H), 1.31-1.13 (m,8H), 1.08 (d, J=6.7Hz, 18H), 0.84 (d, J=6.9Hz, 3H).

EXAMPLE 18(1R*,2S*)-2-(4-Benzyl-4-hydroxypiperidino)-1-(4-hydroxyphenyl)-1-propanol

By the method of Example 3, using ethyl acetate/hexane gradient elutionin chromatography, (1R*,2S*)-title product of the preceding Example(0.46 g, 0.92 mmol) was converted to 0.24 g (74%) of present titleproduct as a monohydrate; mp 173-174° C.; NMR (DMSO d₆ with D₂ O added)7.21-7.12 (m, 5H), 7.04 (d, J=7.6 Hz, 2H), 6.64 (d, J=8.6 Hz, 2H), 4.64(d, J=8.6 Hz, 1H), 2.59 (s, 2H), 2.59-2.49 (m, 5H--partially under NMRsolvent) 1.50-1.31 (m, 4H), 0.82 (d, J=7 Hz, 3H). Anal. C 70.26, H 7.96,N 3.85; calcd. for monohydrate, C 70.17, H 8.13, N 3.90.

EXAMPLE 192-(4-Benzyl-4-hydroxypiperidino)-1-(4-fluoro-phenyl)-1-propanone

Title product, prepared as in Example 10 in 80% yield, wasrecrystallized from ether, mp 119.5-120° C.; Anal. C 73.41, H 7.08, N4.03, calcd. C 73.87, H 7.09, N 4.10.

EXAMPLE 20 (1S*,2S*)- and(1R*,2S*)-2-(4-Benzyl-4-hydroxypiperidino)-1-(4-fluorophenyl)-1-propanol

Title products, prepared as in Example 17, were separated by flashchromatography on silica gel (ethyl acetate-hexane then methanol-ethylacetate gradient). The 1S*,2S* product eluted first in 84% yield as asolid which was recrystallized from ethanol/ether, mp 153.5-154.5° C.Anal. C 73.53, H 7.67, N 4.08, calcd. C 73.44, H 7.63, N 4.08.

The 1R*,2S* product, eluted second in 15% yield, was recrystallized fromethanol/ether, mp 145-146° C.; Anal. C 73.18, H 7.59, N 4.06, calcd. C73.44, H 7.63, N 4.08.

EXAMPLE 212-(3-Phenylmethylene-8-azabicyclo[3.2.1]oct-8-yl)-1-4-benzyloxyphenyl)-1-propanone

Title product, prepared following the procedure of Example 1 from4-benzyloxy-alpha-bromopropiophenone, was obtained in 40-60% yield aftersilica gel flash chromatography; NMR 8.34 (d, 2H), 7.56-7.45 (m, 7H),7.20 (d, 3H), 7.03 (d, 2H), 6.36 (s, 1H), 5.14 (s, 2H), 4.13 (q, 1H),3.56-3.30 (m, 2H), 2.81 (t, 1H), 2.70-2.40 (m, 2H), 2.10-1.76 (m, 3H),1.66 (m, 1H), 1.45 (d, 3H).

EXAMPLE 22 (1S*,2S*)-2-(3-Phenylmethylene-8-azabicyclo[3.2.1]oct-8-yl)-1-(4-benzyloxyphenyl)-1-propanol

Title product, prepared following the procedure of Example 3 with a 1.25hour reaction time, was obtained in pure form by flash chromatography onsilica gel, mp 145-148° C.; Anal. C 81.69, H 7.46, N 3.02, calcd. C81.97, H 7.57, N 3.19.

EXAMPLE 23(1S*,2S*)-2-(3-Benzyl-8-azabicyclo[3.2.1]oct-8-yl)-1-(4-hydroxyphenyl)-1-propanol

Title product of the preceding Example (0.23 g, 0.523 mmol) wasdissolved in tetrahydrofuran (20 ml) and chilled to -78° C. Ammonia (30ml) was condensed into the solution. Sodium (0.06 g, 2.6 mmol) was addedin three portions and a blue solution gradually formed. After 10 minutesthe reaction was quenched with excess ammonium chloride and the mixturewas allowed to warm to ambient temperature with evaporation of theammonia. The residual mixture was concentrated, and the residueextracted with ethyl acetate. Filtration and concentration left 0.24 gof an oily solid which was flash chromatographed on silica gel (6×1inch, ethyl acetate/hexane gradient elution followed by methanolflushing). This gave first recovered starting material followed byproduct (0.071 g). The product was further purified by recrystallization(ethyl acetate/hexane). A portion was spilled during this process but0.005 g of white solid product was obtained as a 1:3 mixture of epimersof the benzyl group; NMR 7.30-7.10 (m, 7H), 6.72 (J=8.5 Hz) and 6.71(J=8.6 Hz) (pair of overlapping d, total 2H), 4.11 (d, J=8.6 Hz, 1H),3.45 (s, 1H), 3.31 and 3.24 (pair of s, 1 H), 2.73 (J=7.3 Hz) and 2.48(J=7.2 Hz) (pair of d, 2H), 2.61 (quintet, J=7.6 Hz, 1H), 2.11 (m, 1H),1.86-1.17 (m, 10H), 0.81 (d, J=6.7 Hz, 3H). HRMS 352.2276, calcd. forMH+352.2278.

EXAMPLE 24

2-(4-Benzyl-4-hydroxypiperidino)-1-(4-chlorophenyl)-1-propanone

Title product, prepared from 4-chloro-alpha-bromopropiophenone,following the procedure of Example 10 in 72% yield, was purified byflash chromatography on silica gel and recrystallized from ether, mp135.5-136° C; Anal. C 70.11, H 6.70, N 3.85, calcd. C 70.48, H 6.76, N3.91.

EXAMPLE 25 (1S*,2S*)- and(1R*,2S*)-2-(4-Benzyl-4-hydroxypiperidino)-1-(4-chlorophenyl)-1-propanol

Title products, prepared following the procedure of Example 17, wereseparated by the same chromatographic procedure. The 1S*,2S* product wasobtained in yield, mp 159.5-160.5° C. (ethanol/ether); Anal. C 70.13, H7.50, N 3.91, calcd. C 70.08, H 7.28, N 3.89.

The 1R*,2S* product was obtained in 7% yield, mp 150.5-151.5° C.(ethanol/ether); Anal. C 69.62, H 7.38, N 3.92, calcd. C 70.08, H 7.28,N 3.89.

EXAMPLE 262-(4-Benzyl-4-hydroxypiperidino)-1-(4-chlorophenyl)-1-ethanone

Title product was prepared following the procedure of Example 10 from4-chloro-alpha-bromoacetophenone in yield; NMR 7.93 (d, J=8.5 Hz, 2H),7.39 (d, J=8.6 Hz, 2H), 7.31-7.16 (m, 5H), 3.74 (s, 2H), 2.74 (s, 2H),2.73-2.71 (m, 2H), 2.43 (dt, J=11.5, 2.4 Hz, 2H), 1.80 (dt, J=12.7, 4.3Hz, 2H), 1.50 (br d, J=13.8 Hz, 2H).

EXAMPLE 27 2-(4-Benzyl-4-hydroxypiperidino)-1-(4-chlorophenyl)ethanol

Title product, prepared from 4-chloro-alpha-bromoacetophenone followingthe procedure of Example 17 in 83% yield, was recrystallized fromethanol/ether, mp 151-152° C.; NMR 7.34-7.18 (m, 9H), 4.67 (dd, J=10.5,3.5 Hz, 1H), 4.18 (br s, 1H), 2.89-2.86 (m, 1H), 2.76 (s, 1H), 2.68-2.47(m, 3H), 2.41-2.31 (m, 2H), 1.73 (dq, J=13.3, 4.4 Hz, 2H), 1.58-1.50 (m,2H), 1.24 (s, 1H).

EXAMPLE 282-(4-Benzyl-4-hydroxypiperidino)-1-(4-fluorophenyl)-1-ethanone

Title product was prepared following the procedure of Example 10 in 59%yield from 4-fluoro-alpha-bromoacetophenone; NMR 8.05-7.99 (m, 2H),7.33-7.04 (m, 7H), 3.76 (s, 2H), 2.83-2.71 (m, 4H), 2.43 (dt, J=11.5,2.1 Hz, 2H), 1.82 (dt, J=12.7, 4.3 Hz, 3H), 1.51 (br d, J=11.5 Hz, 2H).

EXAMPLE 29 2-(4-Benzyl-4-hydroxypiperidino)-1-(4-fluorophenyl)-1-ethanol

Title product, prepared following the procedure of Example 17 in 85%yield, was recrystallized from ethanol/ether, mp 144.5-146° C.; NMR7.35-7.25 (m, 5H), 7.19 (d, J=6.4 Hz, 2H), 7.01 (t, J=8.7 Hz, 2H), 4.67(dd, J=10.5, 3.5 Hz, 1H), 4.18 (br s, 1H), 2.88 (br d, J=11.2 Hz, 1H),2.76 (s, 2H), 2.68-2.31 (m, 5H), 1.81-1.66 (m, 2H), 1.58-1.50 (m, 2H),1.28 (s, 1H).

EXAMPLE 30Endo-1-(4-(Triisopropylsilyoxy)phenyl)-2-(3'-phenylspiro[8-azabicyclo[3.2.1]octane-3,2'-oxirane]-8-yl)-1-propanone

Title product of Preparation 13 below (0.72 g, 3.34 mmol), title productof Preparation 10 below (1.29 g, 3.35 mmol), and potassium carbonate(0.93 g, 6.7 mmol) were combined in tetrahydrofuran (80 ml), refluxedfor 30 hours, cooled and filtered through diatomaceous earth. Thefiltrate was concentrated and chromatographed on silica gel (ethylacetate/hexane gradient elution) to give 0.77 g (44%) of title productas a mixture of diastereomers. The epoxide protons were observed atdelta 3.65 and 3.60 ppm in the NMR spectrum.

The corresponding exo isomer was prepared in like manner from the otherisomer of Preparation 13 in 37% yield. The epoxide protons in themixture of diasteromeric products were observed at 3.80 and 3.86 ppm inthe NMR spectrum.

EXAMPLE 31 Endo- and exo-(1S*,2S*) and(1R*,2S*)-1-(4-(Triisopropylsilyoxy)phenyl)-2-(3'-phenylspiro[8-azabicyclo[3.2.1]octane-3,2'-oxirane]-8-yl)-1-propanol

A mixture of present endo title products was prepared from endo titleproduct of the preceding Example in 82% yield by the procedure ofExample 17. Flash chromatography gave pure, faster running (1S*,2S*)-isomer; NMR 7.34-7.23 (m, 5H), 7.17 (d, J=8.5 Hz, 2H), 6.82 (d,J=8.5 Hz, 2H), 4.02 (d, J=8 Hz, 1H), 3.65 (s, 1H), 3.45 (br s, 1H), 3.28(br s, 1H), 2.65 (quintet, J=7.2 Hz, 1H), 2.54 (dd, J=13.8, 3.2 Hz, 1H),2.15 (q, J=8.6 Hz, 2H), 1.93-1.72 (m, 4H), 1.40 (d, J=13.8 Hz, 2H).Slower running (1R*,2S*)-isomer, which shows a characteristic NMR signalat 4.81 ppm (br s, 1H) was obtained as a mixture with the(1S*,2S*)isomer.

The corresponding exo isomers were prepared in like manner from theexo-isomer of the preceding Example in 82% yield as a 3:1 mixture of(1S*,2S*) and (1R*,2S*) isomers. The epoxide protons were seen at 3.86and 3.82 ppm in the NMR spectrum.

EXAMPLE 32Endo-(1S*,2S*)-1-(4-Hydroxyphenyl)-2-(3'-phenylspiro[8-azabicyclo-[3.2.1]octane-3,2'-oxirane]-8-yl)-1-propanol

By the method of Example 3, endo-(1S*,2S*)-title product of thepreceding Example was converted to present title product in 62% yield;mp 204.5-205° C. (chloroform/hexane); NMR 7.32-7.25 (m, 5H), 7.17 (d, J=8.4 Hz, 2H), 6.73 (d, J=6.6 Hz, 2H), 5.25 (br s, 1H), 4.01 (d, J=8.2Hz, 1H), 3.66 (s, 1H), 3.47 (br s, 1H), 3.31 (br s, 1H), 2.65-2.54 (m,2H), 2.16 (d, J=8 Hz, 2H), 1.89-1.73 (m, 3H), 1.44 (br d, J=13.9 Hz,1H), 1.24 (br d, J=14 Hz, 1H), 0.83 (d, J=6.7 Hz, 3H).

EXAMPLE 33 Endo-1S*,2S*)-2-(3-Benzyl-3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl)-1-(4-(triiisopropylsilyloxy)phenyl)-1-propanol

The endo- (1S*,2S*)/(1R*,2S*) mixture of Example 31 (0.19g, 0.36 mmol)was dissolved in tetrahydrofuran (20 ml) and chilled to -78° C. Ammonia(30 ml) was condensed into the solution and sodium metal (0.08 g) wasadded in small chunks over 1 hour. At this time the mixture turned deepblue. The reaction was stirred 10 minutes longer, then quenched withsolid NH₄ Cl. The ammonia was allowed to evaporate, the residual mixturewas partitioned between ethyl acetate and water, and the aqueous layerwas extracted with fresh ethyl acetate. The combined organic layers werewashed with brine, dried over CaSO₄ and concentrated to give 0.18 g(95%) of a light yellow oil, which was purified by flash chromatographyon silica gel (ethyl acetate/hexane gradient elution) to give 0.1 g ofcolorless oil which was the (1S*,2S*)-title product; NMR 7.33-7.25 (m,3H), 7.18 (d, J=8.3 Hz, 4H), 6.84 (d, J=8.4 Hz, 2H), 4.09 (d, J=7.5 Hz,1H), 3.42 (br s, 1H), 3.13 (br s, 1H), 2.70-2.58 (m, 3H), 2.11-1.91 (m,4 H), 1.73-1.51 (m, 4H), 1.30-1.16 (m, 5H), 1.09 (d, J=6.9 Hz, 18H),0.86 (d, J=6.7 Hz, 3H).

EXAMPLE 34Endo-(1S*,2S*)-2-(3-Benzyl-3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl)-1-(4-hydroxyphenyl)-1-propanol

By the procedure of Example 3, title product of the preceding Examplewas converted to present title product in 38% yield after flashchromatography and recrystallization from ethyl acetate/hexane; mp162-163° C.; ¹³ C-NMR 156.97, 138.80, 135.86, 131.73, 129.11, 128.70,127.07, 115.58, 76.09, 71.74, 64.64, 62.36, 54.62, 52.97, 45.82, 45.68,29.28, 28.85, 14.50.

By the procedure of the preceding Example, the title product of Example32 is converted to the same product.

EXAMPLE 35 Exo-(1S*,2S*)- and(1R*,2S*)-1-(4-hydroxyphenyl)-2-(3'-phenylspiro[8-azabicyclo[3.2.1]octane-3,2'-oxirane]-8-yl)-1-propanol

By the procedure of Example 3, the exo-(1S*,2S*)/(1R*,2S*) mixture ofExample 31 was converted to a mixture of present title products in 93%yield. The (1S*,2S*) isomer was separated by flash chromatography andrecrystallized from ether/hexane, mp 115-117° C. The (1R*,1S*) isomer,obtained as a minor component (about 25%) in later fractions of thechromatography, was also recrystallized from ether/hexane, mp 107-110°C.

EXAMPLE 361-(4-(Triisopropylsilyloxy)phenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanone

By the procedure of Example 1, 4-hydroxy-4-phenylpiperidine wasconverted to present title product in 37% yield as a clear oil; NMR 8.03(d, J=8.5 Hz, 2H), 7.47 (d, J=8 Hz 2H), 7.33 (t, J=7.5 Hz, 2H),7.26-7.24 (m, 1H), 6.89 (d, J=8.5 Hz, 2H), 4.08 (q, J =7.5 Hz, 1H),2.90-2.60 (m, 2H), 2.25-2.10 (m, 2H), 1.85-1.75 (m, 2H), 1.65-1.55 (m,2H), 1.32-1.22 (m, 6H), 1.10 (d, J=7 Hz, 18H).

EXAMPLE 37(1S*,2S*)-1-(4-(Triisopropylsilyloxy)phenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol

By the procedure of Example 17, title product of the preceding Examplewas converted to present title product in 87% yield; mp 148-151° C.; NMR7.52 (d, J=7 Hz, 2H), 7.38 (t, J=7 Hz, 2H), 7.30-7.25 (m, 1H), 7.19 (d,J=8.5 Hz, 2H), 6.84 (d, J=8.5 Hz, 2H), 4.23 (d, J=9.5 Hz, 1H), 3.13-3.02(m, 1H), 2.80-2.58 (m, 3H), 2.30-2.08 (m, 2H), 1.90-1.78 (m, 2H),1.29-1.17 (m, 3H), 1.09 (d, J=7 Hz, 18H), 0.79 (d, J=6.5 Hz, 3H).

EXAMPLE 38(1S*,2S*)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol

Title product, prepared following the procedure of Example 3 from titleproduct of the preceding Example in 65% yield, was recrystallized fromethanol; mp 202-204° C.; Anal. C 71.95, H 8.09, N 4.26, calcd. for 0.5C₂ H₅ OH, C 71.97, H 8.05, N 4.00.

EXAMPLES 39-76

Using the methods of the preceding Examples, the following additionalcompounds were prepared, specifying yield to purified material in thefinal step:

39. 2-(4-Benzyl-4-hydroxypiperidino)-1-(4-hydroxyphenyl)ethanol; 42%; mp98-99° C. (from ethanol).

40.(1S*,2S*)-2-(4-Benzyl-4-hydroxypiperidino)-1-(4-methoxyphenyl)-1-propanol;36%; mp 145.5-146° C. (from ethanol/ether).

41.(1S*,2S*)-2-(4-Benzyl-4-hydroxypiperidino)-1-(4-hydroxyphenyl)-1-pentanol;55%; mp 158-159° C. (from ethanol/ether).

42.(1R*,2S*)-2-(4-Benzyl-4-hydroxpiperidino)-1-(4-hydroxyphenyl)-1-pentanol;37%; mp 156-157° C. (from ether).

43.(1S*,2S*)-2-(4-Benzyl-4-hydroxypiperidino)-1-(4-hydroxyphenyl)-1-butanol;53%; mp 190-191° C. (from ethanol).

44.(1S*,2S*)-2-(4-Benzyl-4-hydroxypiperidino)-1-(4-methoxyphenyl)-1-butanol;61%; mp 143-144° C. (purified by flash chromatography on silica gelusing ethyl acetate/hexane gradient elution).

45. 2-(4-Benzyl-4-hydroxypiperidino)-1-(4-cyanophenyl)ethanol; 52%; mp142-143° C. (from ethanol/ether/hexane).

46. 2-(4-Benzyl-4-hydroxypiperidino)-1-(2-hydroxyphenyl)ethanol; 43%; mp172-173.5° C. (from ethanol).

47. 2-(4-Benzyl-3-hydroxypiperidino)-1-(3-hydroxyphenyl)ethanol; 76%; mp198-199° C. (from ethanol).

48. 1-(4-Chlorophenyl)-2-(4-hydroxy-4-phenyl-piperidino)ethanol; 63%; mp155.5-157° C. (from ethanol/ether).

49.(1S*,2S*)-2-(4-(4-chlorophenyl)-4-hydroxypiperidino)-1-(4-hydroxyphenyl)-1-propanol;58%; mp 204-206° C. (from ethyl acetate).

50. 2-(4-Hydroxy-4-phenylpiperidino)-1-(2-thienyl)ethanol; 54%; mp167-168° C. (from ethanol).

51.(1S*,2S*)-Exo-1-(4-Hydroxyphenyl)-2-(3-(2-thienylthio)-8-azabicyclo[3.2.1]oct-8-yl)-1-propanol;38%; mp 127.5-129° C. (from ethyl acetate/hexane).

52.(1R*,2S*)-Exo-1-(4-Hydroxyphenyl)-2-(3-(2-thienylthio)-8-azabicyclo[3.2.1]oct-8-yl)-1-propanol;19%; mp 141-142.5° C. (from ethyl acetate).

53.(1S*,2S*)-Exo-2-(3-(4-chlorophenylthio)-8-azabicyclo[3.2.1]oct-8-yl)-1-(4-hydroxyphenyl)-1-propanol;84%; mp 181-182.5° C. (from ethyl acetate).

54.(1R*,2S*)-Exo-2-(3-(4-chlorophenylthio)-8-azabicyclo[3.2.1]oct-8-yl)-1-(4-hydroxyphenyl)-1-propanol;94%; mp 154-156° C. (from ethyl acetate/hexane).

55. (1S*,2S*)-Exo-1-(4-Hydroxyphenyl)-2-(3-(4-methoxyphenylthio)-8-azabicyclo[3.2.1]oct-8-yl)-1-propanol; 55%; mp 118-119° C. (fromethyl acetate/hexane).

56. (1R*,2S*)-Exo-1-(4-Hydroxyphenyl)-2-(3-(4-methoxyphenylthio)-8-azabicyclo[3.2.1]oct-8-yl)-1-propanol; 37%; mp 72-75° C. (flashchromatography on silica gel using ethyl acetate/hexane gradient elutionand hexane trituration).

57. 1-(4-Trifluoromethylphenyl)-2-(4-hydroxy-4-phenylpiperidino)ethanol;34%; mp 152-153° C. (from ethanol/ether).

58. 1-(4-Acetamidophenyl)-2-(4-hydroxy-4-phenylpiperidino)ethanol; 34%;mp 217.5-218° C. (from ethanol).

59. (1S*,2S*)-1-(4-hydroxyphenyl)-2-[4-hydroxy-4-(2-phenylethyl)piperidino]-1-propanol; 51%; mp 200-201° C. (from ethyl acetate).

60. (1S*,2S*)-1-(4-Hydroxyphenyl)-2-[4-hydroxy-4-(3-phenylpropyl)piperidino]-1-propanol; 46%; mp 200.5-201° C. (from ethyl acetate).

61. (1S*,2S*)-2-[4-(4-Fluorophenyl)-4-hydroxypiperidino]-1-(4-hydroxyphenyl)-1-propanol; 37%; mp 197-198° C. (from ethylacetate).

62. 1-(4-Cyanophenyl)-2-(4-hydroxy-4-phenylpiperidino)ethanol; 51%; mp140-140.5° C. (from ethanol/ether).

63.(1S*,2S*)-1-(4-Hydroxyphenyl)-2-[4-hydroxy--(4-methylphenyl)piperidino]-1-propanol;41%; mp 188-189° C.

64. 1-(4-Carbamoylphenyl)-2-(4-hydroxy-4-phenylpiperidino)ethanol; 23%mp 213.5-215° C. (from ethanol).

65. (1S*,2S*)-1-(4-Hydroxyphenyl)-2-(3-endohydroxy-3-phenyl-8-azabicyclo[3.2.1]octan-8-yl)-1-propanol; 60%; 216-217° C.(from ethanol/ether).

66.(1S*,2S*)-1-(4-Fluorophenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol;44%; mp 177-179° C. (from ethanol).

67.(1R*,2S*)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol;25%; mp 152-155° C. (from ethanol).

68. (1S*,2S*)-2-(4-Hydroxy-4-phenylpiperidino)-1-phenyl-1-propanol; 50%;mp 149-152° C. (from ethyl acetate/hexane).

69.(1S*,2S*)-1-(4-Chlorophenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol;38%; mp 192-194° C. (from ethanol).

70. 1-(4-Aminophenyl)-2-(4-hydroxy-4-phenylpiperidino)ethanol; 47%; mp156.5-158° C. (from ethyl acetate/ether).

71.(1S*,2S*)-2-(3-Benzyl-3-hydroxypyrrolidino)-4-(4-hydroxyphenyl)-1-propanol;71%; mp 134-136° C.

72.(1S*,2S*)-1-(4-Hydroxyphenyl)-2-(3-hydroxy-3-phenylpyrrolidino)-1-propanol;56% mp 74-78° C.

73.(1S*,2S*)-1-(4-Chlorophenyl)-2-[4-hydroxy-4-(2-phenylethyl)piperidino]-1-propanol;33%; mp 152-154° C. (from ethanol).

74.(1S*,2S*)-1-(4-Hydroxyphenyl)-2-[4-hydroxy-4-(4-Phenylbutyl)piperidino]-1-propanol;44%; mp 191-192° C. (from ethanol).

75. 1-(4-Carboxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)ethanol; 98%; mp254.5-255° C. (from H₂ O). 76.2-(4-Hydroxy-4-phenylpiperidino)-1-[4-(methoxycarbonyl)phenyl]ethanol;57%; mp 138.5-139.5° C. (from ethanol/ether).

EXAMPLE 77 (R-1-(4-Chlorophenyl)-2-(4-hydroxy-4-phenylpiperidino)ethanol

4-Hydroxy-4-phenylpiperidine (177 mg, 1 mmol) was dissolved in drytetrahydrofuran (13 mL) and chilled to -15° C. with stirring and under anitrogen atmosphere. Butyllithium (0.8 ml, 2 mmol, 2.5N) was addeddropwise over 3 minutes. (-)-R-1-(4-chlorophenyl)ethylene oxide [155 mg,1 mmol; J. Am. Chem. Soc. 109, 7925 (1987); J. Org. Chem. 53, 2861(1988)] was dissolved in 1 mL tetrahydrofuran and added to the coldreaction with a 1mL rinse. The mixture was warmed to ambient temperatureand finally refluxed overnight. The mixture was cooled to roomtemperature and quenched with solid NaHCO₃. The crude reaction wasdirectly chromatographed on silica gel using on ethyl acetate-hexanegradient elution. The product containing fractions were carefullyrechromatographed on silica gel with 50% ethyl acetate-hexane elution togive 112 mg (33%) of product as an oily foam. Trituration withether-hexane gave 15.2 mg of cream colored product which had mp 110-113°C.; [alpha]_(D) =-18°.

(S)-1-(4-(Chlorophenyl)-2-(4-hydroxy-4-phenylpiperidino)ethanol, havingthe same physical properties except for sign of rotation was prepared inthe same manner from (+)-S-1-(4-chlorophenyl)ethylene oxide.

EXAMPLE 78 Enantiomeric (1S,2S)- and(1R,2R)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanols

(+)-Tartaric acid (300 mg, 2 mmol) was dissolved in 30 mL warm methanol.Racemic 1S*,2S*-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidinyl)propanol (655 mg, 2 mmol) was addedall at once. With stirring and gentle warming a colorless homogeneoussolution was obtained. Upon standing at ambient temperature 24 hours,319 mg (66%) of a fluffy white precipitate was obtained. This productwas recrystallized from methanol to give 263 mg of the (+)-tartrate saltof levoratatory title product as a white solid; mp 206.5-207.5° C.;[alpha]_(D) =-36.2° C. This salt (115 mg) was added to 50 ml ofsaturated NaHCO₃. Ethyl acetate (5 ml) and the mixture was vigorouslystirred 30 minutes. The aqueous phase was repeatedly extracted withethyl acetate. The organic layers were combined and washed with brine,dried over calcium sulfate, and concentrated. The tan residue wasrecrystallized from ethyl acetate-hexane to give 32 mg (39%) of white,levoratatory title product mp 203-204° C., [alpha]_(D) =-56.9°. Anal.Calcd. for C₂₀ H₂₅ NO₃ : C, 73.37; H, 7.70; N, 4.28. Found: C, 72.61; H,7.45; N, 4.21.

The filtrate from the (+)-tartrate salt preparation above was treatedwith 100 ml saturated aqueous NaHCO and extracted well with ethylacetate. The combined organic extracts were washed with brine, driedover calcium sulfate and concentrated to give 380 mg of recoveredstarting material (partially resolved). This material was treated with(-)-tartaric acid (174 mg) in 30 mL of methanol as above. After standingfor 24 hours, filtration gave 320 mg (66%) of product which was furtherrecrystallized from methanol to produce 239 mg the (-)-tartrate salt ofdextroratatory title product; mp 206.5-207.5° C.; [alpha]_(D) =+33.9°.The latter was converted to dextrotatory title product in the mannerabove in 49% yield; mp 204-205° C.; [alpha]_(D) =+58.4°. Anal. Found: C,72.94; H, 7.64; N, 4.24.

EXAMPLE 79(1S*,2S*)-1-(4-Hydroxyphenyl)-2-(1,2,3,6-tetrahydro-4-phenylpyrido)-1-propanol

By the methods of Examples 1, 2 and 3,4-(triisopropylsilyloxy)-alpha-bromopropiophenone and1,2,3,6-tetrahydro-4-phenylpyridine were converted to present titleproduct in 14% yield in the last step; mp 208-211° C (dec.).

PREPARATION 18-(2,2,2-Trichloroethoxycarbonyl)-3-phenylmethylene-8-azabicyclo[3.2.1.]octane

A solution of benzyltriphenylphosphonium chloride (13.26 g, 34.1 mmol)in tetrahydrofuran (400 ml) was chilled to -78° C. and butyl lithium(13.6 ml of 2.5M in hexanes, 34 mmol) was added. This resulted in aheterogeneous orange mixture which was stirred 5 minutes at -78° C. andthen warmed to 0° C. The solution became nearly homogeneous red andN-2,2,2-trichloroethoxycarbonyltropinone (7.1 g, 23.3 mmol; Montzka etal., Tetrahedron Letters, vol, 14, p. 1325, 1974) was added intetrahydrofuran (20 ml with a 20 ml rinse). The reaction was refluxed 4days, cooled, and filtered. Concentration of the filtrate left a viscousbrown oil. Flash chromatography on silica gel (3×6 inches) using firsthexane and then an ethylacetate/hexane gradient gave 7.87 g of whitesolid product (74%); mp 88-89° C., ir (KBr) 3437, 2958, 1700, 1445,1425, 1321, 1125, 711. Anal. C 54.89, H 4.82, N 3.77, calcd. C 54.49, H4.84, N 3.74.

PREPARATION 2 3-Phenylmethylene-8-azabicyclo[3.2.1]octane

A mixture of title product of the preceding Preparation (1.0 g, 2.67mmol), zinc dust (0.88 , 13.46 mmol), and acetic acid (50 ml) wasstirred overnight. The reaction was then heated at 70° C. for 22 hours,then cooled and concentrated. The residue was partitioned betweenether/ethyl acetate and saturated NaHCO₃, and the mixture stirred 30minutes and then filtered over diatomaceous earth. The aqueous phase wasseparated and further extracted with ethyl acetate (2x). The combinedorganic layers were washed with water and brine, dried (CaSO₄) andconcentrated to leave 0.5 g of light yellow oil. Further purificationwas effected by taking the oil up in 10% HCl. This acid solution wasextracted with ethyl acetate (2x). The acidic layer was neutralized overice with sodium hydroxide and back extracted into ethyl acetate. Thisorganic layer was dried (CaSO₄) and concentrated to leave 0.24 g (48%)of light yellow oil; NMR 7.24 (m, 2H), 7.13 (d, J=6.6 Hz, H), 6.28 (s,1H), 3.52 (br d, J=28.2 Hz, 2H), 2.56 (t, J=15.4 Hz, 3H), 2.26 (d,J=14.7 Hz, 1H), 2.12 (d, J=13.9 Hz, 1H), 1.64 (m, 3H), 1.40 (m, 1H).

Alternatively, the product was converted to its HCl salt by treating anacetone solution with HCl gas.

PREPARATION 3 4-(tert-Butyldimethylsilyloxy)propiophenone

4-Hydroxypropiophenone (15 g, 100 mmol) and imidazole (17 g, 250 mmol)were dissolved in dimethylformamide (50 ml). tert-Butyldimethylsilylchloride (19.6 g, 130 mmol) in dimethylformamide (40 ml) was addeddropwise at ambient temperature. The mixture was stirred 18 hours, thendiluted with water (300 ml) and extracted with ether (4×200 ml). Thecombined ether layers were washed with 1M LiCl and brine, dried (CaSO₄),concentrated to an oily solid, flash chromatographed on silica gel using1:10 ethylacetate:hexane as eluant to yield 26 g of title product whichwas further purified by short path distillation to yield 23.2 g (88%) ofpurified title product as a hygroscopic white solid; mp 30-31° C.; NMR7.76 (d, J=Hz, 2H), 6.74 (d, J=Hz, 2H), 2.82 (q, J =Hz, 2H), 1.09 (t,J=Hz, 3H), 0.87 (s, 9H), 0.11 (s, 6H).

PREPARATION 4 4-(tert-Butyldimethylsilyloxy)-alpha-bromopropiophenone

4-(tert-Butyldimethylsilyloxy)propiophenone (20 g, 75.8 mmol) wasdissolved in acetic acid (300 ml) and bromine (3.9 ml, 75.8 mmol in 30ml of acetic acid) was added dropwise. The orange color of brominepersisted for about 1 minute and then the reaction rapidly decolorizedas the bromine was added. The reaction was stirred 1 hour further, thenconcentrated and the residue flash chromatographed on silica gel (hexaneelution) to give 7.12 g of oily product; NMR 7.92 (d, J =9 Hz, 2H), 6.86(d, J=9 Hz, 2H), 5.22 (q, J=6.5 Hz, 1H), 1.85 (d, J=6.5 Hz, 3H), 0.96(s, 9H), 0.22 (s, 6H). ¹³ C NMR 76.73, 59.55, 40.47, 38.59, 37.68,25.42.

PREPARATION 5 O-Methanesulfonyltropine

Tropine (14.2- g, 100 mmol) was dissolved in CH₂ Cl₂ (210 ml) andtriethylamine (23 ml, 160 mmol) was added. Methanesulfonyl chloride (9.3ml, 120 mmol) was added rapidly dropwise which caused the methylenechloride solution to reflux gently. The mixture was stirred one hourfurther; then extracted with cold 0.5 molar sodium hydroxide, water, andbrine, dried by filtration through phase separating paper andconcentrated to yield 13.8 g (65%) of title product as a yellow solid;NMR 4.88 (t, J=5 Hz, 1H), 3.10-3.05 (m, 2H), 2.94 (s, 3H), 2.22 (s, 3H),2.20-2.10 (m, 2H), 2.02-1.88 (m, 6H).

PREPARATION 6

3-Phenylthio-8-methyl-8-azabicyclo[3.2.1]octane

NaH (60% in oil; 2.77 g, 69 mmol) was washed with hexane (3x) and thensuspended in tetrahydrofuran (300 ml). Thiophenol (6.5 ml, 63 mmol) intetrahydrofuran (25 ml) was added dropwise over 5 minutes. The milkywhite suspension which formed, with hydrogen evolution, was stirred 10minutes and then 0-methanesulfonyltropine (13.8 g, 63 mmol in 25 ml oftetrahydrofuran) was added all at once. The mixture was refluxedovernight, cooled and filtered through diatomaceous earth with etherwash. The filtrate was diluted with ethyl acetate and washed with cold1M NaOH, water, and brine, dried (CaSO₄) and concentrated to yield 11.48g (78%) of title product as a yellow solid; NMR 7.50-7.18 (m, 5H),3.32-3.21 (m, 1H), 3.15-3.09 (m, 2H), 2.25 (s, 3H), 2.02-1.94 (m, 2H),1.79-1.72 (m, 4 H), 1.60-1.51 (m, 2H); ¹³ C NMR 134.8, 132.3, 128.8,126.9, 61.16, 39.21, 38.38, 37.72, 26.42.

PREPARATION 73-Phenylthio-8-(2,2,2-trichloroethoxycarbonyl)-8-azabicyclo[3.2.1]octane

Title product of the preceding Preparation (11.48 g, 49.3 mmol) and K₂CO₃ (0.75 g, 5.4 mmol) were mixed with benzene (200 ml) and2,2,2-trichloroethyl chloroformate (7.5 ml, 54.4 mmol) was addedrapidly. The reaction was refluxed 2 hours, cooled, filtered, andconcentrated. The orange oily residue was dissolved in CH₂ Cl2, washedwith saturated NaHCO₃ and then brine, dried (CaSO₄) and concentrated.The residue was purified by flash chromatography on silica gel (hexaneand then 5% ethyl acetate/hexane elution) to give first unreactedthiophenol from the previous reaction and then title product as a yellowoil (13 g, 67%); NMR 7.42-7.23 (m, 5H), 4.72 (AB q, J=12 Hz, 2H),4.35-4.30 (m, 4H), 2.73 (heptet, J=6 Hz, 1H), 2.05-1.68 M, 6H). The oilwas solidified by trituration with hexane; mp 83-84.5° C.; Anal. C48.47, H 4.58, N 3.49, calcd. C 48.68, H 4.60, N 3.55.

PREPARATION 8 3-Phenylthio-8-azabicyclo[3.2.1]octane

Title product of the preceding Preparation (13.0 g, 33 mmol) wasdissolved in acetic acid (400 ml) and zinc dust (11 g, 168 mmol) wasadded. The mixture was heated to 100° C. overnight, then concentratedand the residue partitioned between CH₂ C₂ and saturated NaHCO₃. Theresulting emulsion was cleared by filtration through diatomaceous earth.The phases were separated and the organic layer was dried through phaseseparating filter paper and concentrated to yield 6.1 g (84%) of titleproduct as a yellow oil which solidified on standing; NMR 7.38-7.36 (m,2H)., 7.29-7.20 (m, 3H), 3.52 (s, 2H), 3.36 (heptet, J=6 Hz, 1H),1.94-1.54 (m, 8H); ¹³ C NMR 134.0, 132.43, 128.83, 127.06, 54.93, 40.81,39.01, 28.98.

PREPARATION 9 4-(Triisopropylsilyloxy)propiophenone

By the method of Preparation 3, 4-hydroxypropiophenone andtriisopropylsilyl chloride were converted to present title product as aclear oil in 100% yield; NMR 7.87 (d, J=8.5 Hz, 2H), 6.89 (d, J=8.5 Hz,2H), 2.94 (q, J=7 Hz, 2H), 1.32-1.15 (m, 3H), 1.20 (t, J=7 Hz, 3H), 1.09(d, J=7 Hz, 18H).

PREPARATION 10 4-(Triisopropylsilyloxy)-alpha-bromopropiophenone

Title product of the preceding Preparation (60.63 g, 198 mmol) wasdissolved in CCl₄ (1100 ml) and a solution of bromine (11 ml, 210 mmolin 60 ml CCl₄) added dropwise. After a portion of the bromine solutionwas added without any noticeable decoloration after 15 minutes, aceticacid (1.0 ml) was added in two portions. The solution decolorized within20 minutes and the addition was completed fairly rapidly. The mixturewas stirred 15 minutes more; then the volatile HBr was partially removedwith the aid of a nitrogen stream. The reaction was poured onto water(600 ml) and the phases were separated. The organic layer was washedwith water, saturated NaHCO₃, water, and brine, dried (CaSO₄), andconcentrated to leave 76.2 g (100%) of present title produced as a clearyellow oil; NMR 7.94 (d, J=9 Hz, 2H), 6.91 (d, J=9 Hz, 2H), 5.24 (q,J=6.5 Hz, 1H), 1.87 (d, J=6.5 Hz, 2H), 1.33-1.17 (m, 3H), 1.10 (d, J=7Hz, 18H).

PREPARATION 11 4-Fluoro-alpha-bromopropiophenone

Title product, prepared as in Preparation 4 in 86% yield afterdistillation, was recrystallized from ethanol to afford a whitecrystalline solid; mp 33-34° C. Anal. C 46.67, H 3.38, calcd. C 46.78, H3.49.

PREPARATION 12 4-Chloro-alpha-bromopropiophenone

The product, prepared following the procedure of Preparation 10 in 98%yield, was recrystallized from ethanol, mp 78-79° C.; Anal. C 43.74, H3.17, calcd. C 43.67, H 3.26.

PREPARATION 13 Endo- andExo-8-(2,2,2-Tichloroethoxycarbonyl)-3'phenylspiro[8-azabicyclo[3.2.1]octane-3,2'-oxirane]

The title product of Preparation 2 (5.0 g, 13.34 mmol) was dissolved inCH₂ Cl₂ (80 ml) and m-chloroperbenzoic acid (2.71 g, 13.35 mmol, 85%purity) added. After stirring at ambient temperature overnight, themixture was extracted with saturated NaHCO₃, then with water and brine,dried through phase separating paper, and concentrated to give 5.3 g ofa glassy yellow oil which was chromatographed on silica gel (ethylacetate/hexane gradient elution). Recovered starting material was elutedfirst followed by a fast moving endo epoxide product (2.23 g, 42.8%); mp78-79° C.; Anal. C 52.75, H 4.44, N 3.20, calcd. C 52.26, H 4.64, N3.59; and finally by a slow moving exo epoxide product (2.32 g, 44.5%);mp 107-108° C.; Anal. C 52.34, H 4.40, N 3.54, calcd. as for endoisomer.

PREPARATION 14 Endo- and exo-3'-Phenylspiro[8-azabicyclo[3.2.1]octane-3,2'-oxirane]

The fast moving endo product of the preceding Example (1.55 g, 3.97mmol) was dissolved in tetrahydrofuran (30 ml) and zinc powder (9.3 g,142 mmol) and 1 molar monopotassium phosphate (10 ml) were added. Afterstirring overnight, the mixture was diluted with water (10 ml), the pHadjusted to 10-11 with NaCO₃ and filtered over diatomaceous earth withethyl acetate and water wash. The aqueous layer in the combined filtrateand washes was separated and washed with fresh ethyl acetate. Thecombined organic layers were washed with brine, dried (CaSO₄) andstripped to yield 0.85 g (100%) of endo-title product as a yellow oil.Short path distillation (110-115° C. bath temperature, 0.5 mm) gave endotitle product as a clear colorless oil; NMR 7.34-7.23 (m, 5H), 3.63-3.60(m, 2H), 3.55 (m, 1H), 2.36 (dd, J=14.1, 3.5 Hz, 1H), 2.17-2.12 (m, 2H),1.83-1.81 (m, 2H), 1.70-1.61 (m, 2H), 1.42 (dt, J=11.9, 2.2 Hz, 1H),1.18 (dt, J=14.5, 2.3 Hz, 1H). HRMS 215.1301, calcd. 215.1308.

By the same method, the slow moving isomer of the preceding Preparationwas converted to the corresponding exo isomer in 96% yield, purified byshort path distillation (110-125° C. bath temperature, 0.8 mm); mp114.5-116° C. Anal. C 77.97, H 8.05, N 6.44, calcd. C 78.10, H 7.96, N6.51.

I claim:
 1. A compound of the formula ##STR26## wherein R is H, (C₁-C₆)alkyl, (C₂ -C₆)alkenyl or (C₂ -C₆)alkynyl;Q is S or CH═CH; X ishydrogen(C₁ -C₃)alkyl, halo, OR¹, CO₂ R¹, SR¹, NHR¹ NHCOR¹, CONH₂ or CN;R¹ is hydrogen or (C₁ -C₃)alkyl; Y and Y¹ are taken together and are##STR27## Y and Y¹ are taken separately and Y is hydrogen or OH, and Y¹is ##STR28## n is 0, 1, 2 or 3: m is 0, 1, 2, 3 or 4: Q¹ isindependently a value of Q as defined above; and X¹ is independently avalue of X as defined above; ora pharmaceutically acceptable acidaddition salt thereof.
 2. A compound of claim 1 wherein R is methylhaving 1S*,2S* relative stereochemistry: ##STR29##
 3. A compound ofclaim 1 wherein Q is CH═CH and X is 4-hydroxy.
 4. A compound of claim 2wherein Q is CH═CH and X is 4-hydroxy.
 5. The compound of claim 4wherein Y and Y¹ are taken together and are phenylmethylene.
 6. Thecompound of claim 4 wherein Y and Y¹ are taken together and are##STR30##
 7. A compound of claim 4 wherein Y and Y¹ are takenseparately.
 8. A compound of claim 7 wherein Y is H or OH and Y¹ isbenzyl.
 9. A pharmaceutical composition comprising a neuroprotectiveacceptable carrier.
 10. A method of treating stroke or a CNSdegenerative disease in man which comprises treatment with aneuroprotective amount of a compound of claim 1.